The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Women’s Health Initiative Observational Study
Open accessAbstract
BACKGROUND: In the Women's Health Initiative (WHI) randomized trial, estrogen plus progestin increased both breast cancer incidence and mortality. In contrast, most observational studies associate estrogen plus progestin with favorable prognosis breast cancers. To address differences, a cohort of WHI observational study participants with characteristics similar to the WHI clinical trial was studied. METHODS: We identified 41 449 postmenopausal women with no prior hysterectomy and mammogram negative within 2 years who were either not hormone users (n = 25 328) or estrogen and progestin users (n = 16 121). Multivariable-adjusted Cox proportional hazard regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CI). All statistical tests were two-sided. RESULTS: After a mean of 11.3 (SD = 3.1) years, with 2236 breast cancers, incidence was higher in estrogen plus progestin users than in nonusers (0.60% vs 0.42%, annualized rate, respectively; HR = 1.55, 95% CI = 1.41 to 1.70, P < .001). Women initiating hormone therapy closer to menopause had higher breast cancer risk with linear diminishing influence as time from menopause increased (P < .001). Survival after breast cancer, measured from diagnosis, was similar in combined hormone therapy users and nonusers (HR = 1.03, 95% CI = 0.79 to 1.35). On a population basis, there were somewhat more deaths from breast cancer, measured from cohort entry (HR = 1.32, 95% CI = 0.90 to 1.93, P = .15), and more all-cause deaths after breast cancer (HR = 1.65, 95% CI = 1.29 to 2.12, P < .001) in estrogen plus progestin users than in nonusers. CONCLUSIONS: Consistent with WHI randomized trial findings, estrogen plus progestin use is associated with increased breast cancer incidence. Because prognosis after diagnosis on combined hormone therapy is similar to that of nonusers, increased breast cancer mortality can be expected.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322401 · Cited by 1,487 · cited 2×
“These findings were similar to observational study results regarding incidence (4) but differ from most reports regarding tumor characteristics and clinical outcome, in which a decrease (5–8) in deaths after breast cancer is commonly, but not universally (9), seen.”
BackgroundResultFournier, A., Berrino, F., & Clavel-Chapelon, F. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9523-x · Cited by 693
Cited by
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Global Cancer Incidence and Mortality Rates and Trends—An Update
Torre, L. A., Siegel, R. L., Ward, E. M., & Jemal, A. (2016) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0578 · Cited by 3,692
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884
Formation and Biological Targets of Quinones: Cytotoxic versus Cytoprotective Effects
Bolton, J. L., & Dunlap, T. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00256 · Cited by 522
Pathogenesis, prevention, diagnosis and treatment of breast cancer
Shah, R. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.283 · Cited by 329
Metadata
- Authors
- Chlebowski, R. T., Manson, J. E., Anderson, G. L., Cauley, J. A., Aragaki, A. K., Stefanick, M. L., Lane, D. S., Johnson, K. C., Wactawski-Wende, J., Chen, C., Qi, L., Yasmeen, S., Newcomb, P. A., & Prentice, R. L.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-04-08
- Volume
- 105
- Issue
- 8
- Pages
- 526-535
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2148194373
- Cited by
- 205
- References
- 3
- FWCI
- 17.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Women’s Health Initiative Observational Study. https://app.cochat.ai/papers/10.1093/jnci/djt043
- The paper
- Chlebowski, R. T., Manson, J. E., Anderson, G. L., Cauley, J. A., Aragaki, A. K., Stefanick, M. L., Lane, D. S., Johnson, K. C., Wactawski-Wende, J., Chen, C., Qi, L., Yasmeen, S., Newcomb, P. A., & Prentice, R. L. (2013). Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Women’s Health Initiative Observational Study. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djt043
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.